

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

### To The Board of Directors of Dr. Lal PathLabs Limited

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Dr. Lal PathLabs Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter and nine months ended 31 December, 2021 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the entities listed in Annexure A.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



# Deloitte Haskins & Sells LLP

6. The consolidated unaudited financial results includes the interim financial information/ financial results of four subsidiaries which have not been reviewed by their auditors, whose interim financial information/ financial results reflect total revenue of Rs. 46 million and Rs. 152 million for the quarter and nine months ended 31 December, 2021 respectively, total (loss) after tax of Rs. (11) million and Rs. (16) million for the quarter and nine months ended 31 December, 2021 respectively and total comprehensive (loss) of Rs. (11) million and Rs. (16) million for the quarter and nine months ended 31 December, 2021 respectively, as considered in the Statement. According to the information and explanations given to us by the Management, these interim financial information/ financial results are not material to the Group.
7. Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information/ financial results certified by the Management.

**For Deloitte Haskins & Sells LLP**  
Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



**Jitendra Agarwal**  
Partner  
(Membership No. 87104)  
(UDIN: 22087104ABEBPL4710)

Place: New Delhi  
Date: 10 February, 2022

# Deloitte Haskins & Sells LLP

## Annexure A

### List of entities consolidated

a) **Parent Company:** Dr. Lal PathLabs Limited


### b) Subsidiaries held directly

| S. No. | Name of the Entity   |
|--------|--|
| 1      | Paliwal Diagnostics Private Limited                                    |
| 2      | Paliwal Medicare Private Limited                                       |
| 3      | APL Institute of Clinical Laboratory & Research Private Limited        |
| 4      | Dr. Lal PathLabs Nepal Private Limited                                 |
| 5      | Dr. Lal PathLabs Bangladesh Pvt. Ltd.                                  |
| 6      | Dr. Lal Ventures Private Limited                                       |
| 7      | PathLabs Unifiers Private Limited                                      |
| 8      | Dr. Lal PathLabs Kenya Private Limited                                 |
| 9      | Suburban Diagnostics (India) Private Limited (w.e.f 12 November, 2021) |

### c) Subsidiaries held indirectly

| S. No. | Name of the Entity   |
|--------|--|
| 1      | Centrapath Labs Private Limited                            |
| 2      | APRL PathLabs Private Limited                              |
| 3      | Chanre Laboratory Private Limited (w.e.f 25 January, 2021) |





Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085, New Delhi

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon - 122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

Statement of Consolidated Unaudited Financial Results for the quarter and nine months ended 31 December, 2021

(Rs. in million except as stated)

| Particulars  | 3 months ended<br>31 December, 2021 | Preceding 3 months<br>ended<br>30 September, 2021 | Corresponding 3<br>months ended<br>31 December, 2020 | Year to date figures for<br>the current period ended<br>31 December, 2021 | Year to date figures for<br>the previous period<br>ended 31 December,<br>2020 | Previous year ended<br>31 March, 2021 |
|--|-------------------------------------|---|--|---|---|---------------------------------------|
|  | (Unaudited)                         | (Unaudited)                                       | (Unaudited)  | (Unaudited)   | (Unaudited)   | (Audited)                             |
| <b>1 Income</b>  |                                     |   |  |   |   |                                       |
| (a) Revenue from operations  | 4,969                               | 4,984   | 4,524  | 16,019  | 11,503  | 15,813                                |
| (b) Other income   | 121                                 | 143   | 135  | 405   | 378   | 513                                   |
| <b>Total income</b>  | <b>5,090</b>                        | <b>5,127</b>                                      | <b>4,659</b>   | <b>16,424</b>   | <b>11,881</b>   | <b>16,326</b>                         |
| <b>2 Expenses</b>  |                                     |   |  |   |   |                                       |
| (a) Cost of materials consumed   | 1,189                               | 1,244   | 1,098  | 3,884   | 2,940   | 3,973                                 |
| (b) Employee benefits expense  | 973                                 | 836   | 693  | 2,674   | 1,976   | 2,737                                 |
| (c) Finance costs  | 91                                  | 47  | 39   | 183   | 116   | 160                                   |
| (d) Depreciation and amortisation expense  | 307                                 | 205   | 195  | 704   | 569   | 772                                   |
| (e) Fees to collection centers/channel partners  | 643                                 | 699   | 604  | 2,263   | 1,458   | 2,043                                 |
| (f) Other expenses   | 1,072                               | 790   | 741  | 2,802   | 1,986   | 2,697                                 |
| <b>Total expenses</b>  | <b>4,275</b>                        | <b>3,821</b>                                      | <b>3,370</b>   | <b>12,510</b>   | <b>9,045</b>  | <b>12,382</b>                         |
| <b>3 Profit before tax</b>   | <b>815</b>                          | <b>1,306</b>                                      | <b>1,289</b>   | <b>3,914</b>  | <b>2,836</b>  | <b>3,944</b>                          |
| <b>4 Tax expense</b>   |                                     |   |  |   |   |                                       |
| (a) Current tax  | 213                                 | 344   | 336  | 1,078   | 765   | 1,021                                 |
| (b) Deferred tax   | 20                                  | (1)   | (6)  | (46)  | (43)  | (42)                                  |
| <b>Total tax expense</b>   | <b>233</b>                          | <b>343</b>  | <b>330</b>   | <b>1,032</b>  | <b>722</b>  | <b>979</b>                            |
| <b>5 Profit for the period (A)</b>   | <b>582</b>                          | <b>963</b>  | <b>959</b>   | <b>2,882</b>  | <b>2,114</b>  | <b>2,965</b>                          |
| <b>6 Other comprehensive income</b>  |                                     |   |  |   |   |                                       |
| Items that will not be reclassified to profit or loss                                  | (14)                                |   |  |   |   |                                       |
| -Remeasurement of the defined benefit obligations                                      |                                     | (28)  | -  | (44)  | 1   | (9)                                   |
| -Income tax in relation to the items that will not be reclassified to profit or loss   | 2                                   | 8   | -  | 12  | -   | 2                                     |
| Items that may be reclassified to profit or loss                                       | -                                   | -   | -  | -   | (1)   | (1)                                   |
| -Exchange differences on translation of foreign operations                             |                                     |   |  |   |   |                                       |
| <b>Total other comprehensive income/ (loss) (B)</b>                                    | <b>(12)</b>                         | <b>(20)</b>                                       | <b>-</b>   | <b>(32)</b>   | <b>-</b>  | <b>(8)</b>                            |
| <b>7 Total comprehensive income (A+B)</b>  | <b>570</b>                          | <b>943</b>  | <b>959</b>   | <b>2,850</b>  | <b>2,114</b>  | <b>2,957</b>                          |
| <b>Profit for the period attributable to:</b>  |                                     |   |  |   |   |                                       |
| Owners of the Company  | 573                                 | 950   | 945  | 2,835   | 2,082   | 2,916                                 |
| Non-controlling interest   | 9                                   | 13  | 14   | 47  | 32  | 49                                    |
|  | <b>582</b>                          | <b>963</b>  | <b>959</b>   | <b>2,882</b>  | <b>2,114</b>  | <b>2,965</b>                          |
| <b>Other comprehensive income for the period attributable to:</b>                      |                                     |   |  |   |   |                                       |
| Owners of the Company  | (12)                                | (20)  | -  | (32)  | -   | (8)                                   |
| Non-controlling interest   | -                                   | -   | -  | -   | -   | -                                     |
|  | <b>(12)</b>                         | <b>(20)</b>                                       | <b>-</b>   | <b>(32)</b>   | <b>-</b>  | <b>(8)</b>                            |
| <b>Total comprehensive income for the period attributable to:</b>                      |                                     |   |  |   |   |                                       |
| Owners of the Company  | 561                                 | 931   | 945  | 2,803   | 2,082   | 2,908                                 |
| Non-controlling interest   | 9                                   | 12  | 14   | 47  | 32  | 49                                    |
|  | <b>570</b>                          | <b>943</b>  | <b>959</b>   | <b>2,850</b>  | <b>2,114</b>  | <b>2,957</b>                          |
| <b>8 Paid-up equity share capital (Face value of Rs. 10 per share)</b>                 | <b>833</b>                          | <b>833</b>  | <b>833</b>   | <b>833</b>  | <b>833</b>  | <b>833</b>                            |
| <b>9 Other equity</b>  |                                     |   |  |   |   | <b>11,617</b>                         |
| <b>10 Earnings per share (Rs.)</b><br>(Face value of Rs. 10 per share)(not annualised) |                                     |   |  |   |   |                                       |
| -Basic   | 6.93                                | 11.49   | 11.44  | 34.27   | 25.23   | 35.33                                 |
| -Diluted   | 6.90                                | 11.45   | 11.41  | 34.15   | 25.16   | 35.25                                 |

For identification Only


Deloitte Haskins & Sells LLP

**Dr. Lal PathLabs Limited**

**Notes:**

- i. The above consolidated results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 10 February, 2022. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended December 31, 2021 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. The above consolidated results represent consolidated results of the Company and its subsidiaries (together referred to as 'the Group').
- iii. These financial results of the Group have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iv. The financial results for the quarter and nine months ended 31 December, 2021 are not strictly comparable with the results of quarter ended 30 September, 2021 and quarter and nine months ended 31 December, 2020, due to resurgent wave of COVID-19 in quarter ended 30 June, 2021, nationwide lockdown in the corresponding previous nine month period and acquisition of Suburban Diagnostics (India) Private Limited ("SDIPL") during the current quarter as indicated in note (viii.) below.
- v. The Board of Directors of the Parent Company had approved the first interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 30 July, 2021 which had been paid during the quarter ended September 30, 2021.
- vi. The Board of Directors of the subsidiaries, Paliwal Medicare Private Limited (PMPL) and Paliwal Diagnostics Private Limited (PDPL) in their meetings held on 25 October, 2021 and 25 October, 2021 respectively have approved the "Scheme of Amalgamation" of PMPL with PDPL w.e.f. 1 April, 2021, the appointed date. As per the said scheme, the undertaking of PMPL shall stand transferred to and vested in PDPL on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the shareholders of the respective companies, National Company Law Tribunal and other statutory approvals.
- vii. The Board of Directors of the Parent Company and one of the subsidiary company's 'APL Institute of Clinical Laboratory & Research Private Limited' ("APL"), in their respective meetings held on 3 February, 2020 have approved the "Scheme of Amalgamation" of APL with the Parent Company w.e.f. 1 April, 2020 (the appointed date). As per the said scheme the undertaking of APL shall stand transferred to and vested in the Parent Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the National Company Law Tribunal and other statutory approvals.
- viii. The Parent Company has completed the acquisition of Suburban Diagnostics (India) Private Limited ("SDIPL") on November 12, 2021 as per the terms and conditions of the Share Purchase Agreement for a cash consideration of Rs. 9,250 million plus certain performance linked payments capped at Rs. 2,250 million subject to certain adjustments. Pursuant to completion of the aforesaid acquisition, Suburban Diagnostics (India) Private Limited has now become a wholly-owned subsidiary of the Parent Company. SDIPL is primarily engaged in providing diagnostics and healthcare services.
- ix. The Board of Directors of the Group, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108 - 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- x. The Indian Parliament has approved the Code on Social Security, 2020 ('the Code') which, inter alia, deals with employee benefits during employment and post-employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified. In view of this, the Group is in the process of assessing the impact of the relevant provisions.

For and on behalf of the Board of Directors of  
**Dr. Lal PathLabs Limited**

  
**(Hon'ble) Brig. Dr. Arvind Lal**  
Executive Chairman

Place: Gurugram

Date: 10 February, 2022

For identification Only

  
Deloitte Haskins & Sells LLP

## INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

### To The Board of Directors of Dr. Lal PathLabs Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Dr. Lal PathLabs Limited** ("the Company"), for the quarter and nine months ended 31 December, 2021 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Deloitte Haskins & Sells LLP**


Chartered Accountants  
(Firm's Registration No. 117366W/W-100018)



**Jitendra Agarwal**

Partner  
(Membership No. 87104)  
(UDIN: 22087104ABEBFP2747)

Place: New Delhi  
Date: 10 February, 2022



Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388

Regd. Office : Block E, Sector-18, Rohini, New Delhi- 110085

Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurgaon – 122 001, Haryana

Phone: +91 124 3016500 | Fax: +91 124 4234468; Website: www.lalpathlabs.com; Email: cs@lalpathlabs.com

## Statement of Standalone Unaudited Financial Results for the quarter and nine months ended 31 December, 2021

(Rs. in million except as stated)

| Particulars  | 3 months ended<br>31 December, 2021 | Preceding 3<br>months ended<br>30 September,<br>2021 | Corresponding 3<br>months ended<br>31 December, 2020 | Year to date figures<br>for the current<br>period ended 31<br>December, 2021 | Year to date figures<br>for the previous<br>period ended 31<br>December, 2020 | Previous year<br>ended<br>31 March, 2021 |
|--|-------------------------------------|--|--|--|---|--|
|  | (Unaudited)                         | (Unaudited)  | (Unaudited)  | (Unaudited)  | (Unaudited)   | (Audited)                                |
| <b>1 Income</b>  |                                     |  |  |  |   |  |
| (a) Revenue from operations  | 4,225                               | 4,704  | 4,271  | 14,578   | 10,864  | 14,905                                   |
| (b) Other income   | 113                                 | 153  | 146  | 401  | 382   | 513                                      |
| <b>Total income</b>  | <b>4,338</b>                        | <b>4,857</b>   | <b>4,417</b>   | <b>14,979</b>  | <b>11,246</b>   | <b>15,418</b>                            |
| <b>2 Expenses</b>  |                                     |  |  |  |   |  |
| (a) Cost of materials consumed   | 1,034                               | 1,179  | 1,028  | 3,550  | 2,774   | 3,739                                    |
| (b) Employee benefits expense  | 811                                 | 781  | 653  | 2,400  | 1,862   | 2,574                                    |
| (c) Finance costs  | 87                                  | 43   | 37   | 174  | 109   | 148                                      |
| (d) Depreciation and amortisation expense  | 189                                 | 181  | 178  | 538  | 519   | 698                                      |
| (e) Fees to collection centers/channel partners                                      | 533                                 | 685  | 594  | 2,118  | 1,435   | 2,007                                    |
| (f) Other expenses   | 852                                 | 729  | 686  | 2,456  | 1,853   | 2,511                                    |
| <b>Total expenses</b>  | <b>3,506</b>                        | <b>3,598</b>   | <b>3,176</b>   | <b>11,236</b>  | <b>8,552</b>  | <b>11,677</b>                            |
| <b>3 Profit before tax</b>   | <b>832</b>                          | <b>1,259</b>   | <b>1,241</b>   | <b>3,743</b>   | <b>2,694</b>  | <b>3,741</b>                             |
| <b>4 Tax expense</b>   |                                     |  |  |  |   |  |
| (a) Current tax  | 192                                 | 326  | 327  | 1,008  | 741   | 985                                      |
| (b) Deferred tax   | 23                                  | (6)  | (13)   | (54)   | (61)  | (45)                                     |
| <b>Total tax expense</b>   | <b>215</b>                          | <b>320</b>   | <b>314</b>   | <b>954</b>   | <b>680</b>  | <b>940</b>                               |
| <b>5 Profit for the period (A)</b>   | <b>617</b>                          | <b>939</b>   | <b>927</b>   | <b>2,789</b>   | <b>2,014</b>  | <b>2,801</b>                             |
| <b>6 Other comprehensive income</b>  |                                     |  |  |  |   |  |
| Items that will not be reclassified to profit or loss                                | (14)                                | (28)   | -  | (44)   | 2   | (9)                                      |
| -Remeasurement of the defined benefit obligations                                    |                                     |  |  |  |   |  |
| -Income tax in relation to the items that will not be reclassified to profit or loss | 3                                   | 8  | -  | 12   | (1)   | 2  |
| <b>Total other comprehensive income/(loss) (B)</b>                                   | <b>(11)</b>                         | <b>(20)</b>  | <b>-</b>   | <b>(32)</b>  | <b>1</b>  | <b>(7)</b>                               |
| <b>7 Total comprehensive income (A+B)</b>  | <b>606</b>                          | <b>919</b>   | <b>927</b>   | <b>2,757</b>   | <b>2,015</b>  | <b>2,794</b>                             |
| <b>8 Paid-up equity share capital (Face value of Rs. 10 per share)</b>               | <b>833</b>                          | <b>833</b>   | <b>833</b>   | <b>833</b>   | <b>833</b>  | <b>833</b>                               |
| <b>9 Other equity</b>  |                                     |  |  |  |   | <b>11,338</b>                            |
| <b>10 Earnings per share (Rs.) (Face value of Rs. 10 per share) (not annualised)</b> |                                     |  |  |  |   |  |
| - Basic  | 7.46                                | 11.36  | 11.23  | 33.71  | 24.41   | 33.93                                    |
| - Diluted  | 7.43                                | 11.31  | 11.20  | 33.60  | 24.34   | 33.85                                    |

For identification Only


Deloitte Haskins &amp; Sells LLP

**Dr. Lal PathLabs Limited**

**Notes:**

- i. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 10 February, 2022. The limited review, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, has been completed by the Statutory Auditors for the quarter and nine months ended 31 December, 2021 and they have expressed an unmodified conclusion on the aforesaid results.
- ii. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- iii. During the nine months ended 31 December, 2021, the Company has made a further investment of INR 45 million in its wholly owned subsidiary, PathLabs Unifiers Private Limited, through subscription of additional equity shares.
- iv. During the quarter and nine months ended 31 December, 2021 the Company has made a further investment of INR 1 million (KES 1.48 million) in its wholly owned subsidiary, Dr. Lal PathLabs Kenya Private Limited, through subscription of additional equity shares.
- v. The Company has completed the acquisition of Suburban Diagnostics (India) Private Limited ("SDIPL") on November 12, 2021 as per the terms and conditions of the Share Purchase Agreement for a cash consideration of Rs. 9,250 million plus certain performance linked payments capped at Rs. 2,250 million subject to certain adjustments. Pursuant to completion of the aforesaid acquisition, Suburban Diagnostics (India) Private Limited has now become a wholly-owned subsidiary of the Company. SDIPL is primarily engaged in providing diagnostics and healthcare services.
- vi. The financial results for the quarter and nine months ended 31 December, 2021 are not strictly comparable with the results of quarter ended 30 September, 2021 and quarter and nine months ended 31 December, 2020, due to resurgent wave of COVID-19 in quarter ended 30 June, 2021, nationwide lockdown in the corresponding previous nine month period and acquisition of Suburban Diagnostics (India) Private Limited ("SDIPL") during the current quarter as indicated in note (v.) above.
- vii. The Board of Directors in their meeting held on 3 February, 2020 had approved the "Scheme of Amalgamation" of "APL Institute of Clinical Laboratory & Research Private Limiter (APL) with the Company w.e.f. 1 April, 2020 (the appointed date). As per the said scheme, the undertaking of APL shall stand transferred to and vested in the Company on a going concern basis without any further act, deed of matter. The scheme of amalgamation is subject to approval by the shareholders, National Company Law Tribunal and other statutory approvals.
- viii. The Board of Directors of the Company had approved the first interim dividend of INR 6 per equity share (face value of INR 10 each) at their meeting held on 30 July, 2021 which had been paid during the quarter ended September 30, 2021.
- ix. The Board of Directors of the Company, which has been identified as being the chief operating decision maker (CODM), evaluates the Company's performance, allocates resources based on the analysis of the various performance indicators of the Company as a single unit. Therefore there is no reportable segment for the Company, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', notified under the Companies (Indian Accounting Standard) Rules, 2015.
- x. The Indian Parliament has approved the Code on Social Security, 2020 ('the Code') which, inter alia, deals with employee benefits during employment and post-employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified. In view of this, the Company is in the process of assessing the impact of the relevant provisions.

For and on behalf of the Board of Directors of  
**Dr. Lal PathLabs Limited**

  
**(Hon'ry) Brig. Dr. Arvind Lal**  
Executive Chairman

Place: Gurugram  
Date: 10 February, 2022

For identification Only

 Type text here  
Deloitte Haskins & Sells LLP